Almac invests £500,000 in state-of-the-art instrumentation within spectroscopy laboratories
January 17, 2025
Almac Sciences, a member of the Almac Group, has invested £500,000 in state-of-the-art instrumentation within its spectroscopy laboratories at its global headquarters in Craigavon, Northern Ireland.
Almac is committed to providing the best analytical facilities for its customers and the recent purchase of the new Agilent 6545XT AdvanceBio Q-TOF Mass Spectrometer and a Malvern Panalytical Empyrean X-Ray Powder Diffractometer supports this goal.
This latest investment is additional to the company’s announcement in October 2024 of an £11million spend to expand Almac’s global analytical services capabilities, which includes the creation of 100 jobs.
The Craigavon laboratories house state-of-the-art Mass Spectrometers, X-Ray Powder Diffractometers as well as Nuclear Magnetic Resonance Spectrometers. These investments substantially increase the company’s capabilities in solving complex analytical challenges and provide additional security for urgent analyses, additional processing capabilities, and superior data integrity controls to ensure increasing regulatory compliance needs are met.
Within the dedicated facility, equipped with advanced LC-MS, GC-MS, ICP-MS, XRPD and NMR instrumentation, clients can benefit from a range of spectrometry services, including the quantitation of genotoxic impurities, trace elemental analysis, isotopic purity determinations, structure elucidation, analysis of peptides, proteins, glycoproteins and antibody products as well as polymorph screening, confirmation and quantitation of crystalline phases.
Dr John Malone, Associate Director of Spectroscopy, Almac Sciences said: “The continued investment and growth in our spectroscopy laboratories underlines Almac’s commitment to providing the best analytical facilities for its customers, and seamlessly meeting their needs. We are delighted to offer our clients cutting-edge technology that supports their product safety imperative and accelerates the drug development cycle.”
Dr Darren Thomas, Vice President of Analytical Operations commented: “As we continue to enhance our analytical capabilities, our commitment to excellence remains unwavering. This substantial investment in cutting-edge technology emphasises our dedication to offering comprehensive analytical solutions to clients around the world.”
Share
